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To the Editor:
I am writing in reference to the article by Ruan et al 1 in this issue of CHEST (see page 1462). Th e authors con ducted an interesting meta-analysis assessing the prognostic value of heart-type fatty acid-binding protein (H-FABP) in acute pulmonary embolism (PE). 1 Acute PE is a common and fatal disease. Goldhaber et al 2 reported a 90-day mortality rate of about 52% in hemodynamically unstable patients and 14.7% in patients who are hemodynamically stable. Patients who are hemodynamically stable at the time of admission but manifest right ventricular dysfunction (RVD) have poor prognosis when compared with patients without RVD. 3 Although thrombolytics are recommended in the treatment of hemodynamically unstable patients, there are, at present, no guidelines for the management of patients who are hemodynamically stable but have RVD. Risk stratifi cation of patients with acute PE is critical for optimal management and enhanced outcomes. H-FABP may support clinicians in the stratifi cation of high-risk patients as well as in the development of recommendations to manage these patients.
Ruan et al 1 included fi ve prospective studies in the meta-analysis. Th ey compared 30-day mortality and 30-day complicated clinical events (CCEs) in patients with acute PE demonstrating elevated H-FABP levels (above cutoff ) with patients with normal H-FABP levels (below cutoff). Of the five studies used, however, two, by Dellas et al 4 Similarly, Ruan et al 1 reported prognostic sensitivity of 98% and specificity of 77% for the 30-day mortality. In predicting serious events at 30 days, the prognostic sensitivity and specifi city was found to be at 86% and 82%, respectively. Again, excluding the Puls et al 5 study results in change of sensitivity and specifi city for both 30-day mortality and CCE ( Table 1 ) . 
